Estrogen Protects Against Growth Hormone's Own Negative Feedback in Postmenopausal Women | Research

The takeaway

Short-term estradiol replacement in postmenopausal women selectively blocked GH's autonegative feedback on GHRP-2-stimulated secretion, explaining women's higher GH output and supporting sex-specific GH therapy approaches.

Pathway-specific
Estrogen protected GHRP-2-stimulated GH from feedback inhibition but did NOT protect GHRH-stimulated GH — exquisite pathway selectivity

What the researchers found

Estradiol replacement selectively relieved GH autonegative feedback on GHRP-2-stimulated (not GHRH-stimulated) GH secretion in postmenopausal women, demonstrating pathway-specific estrogen modulation of the somatotropic axis.

Why it matters

Understanding how estrogen modulates GH feedback is essential for optimizing GH secretagogue therapy in women — particularly postmenopausal women who are most likely to need GH enhancement.

How the study worked

RCT in postmenopausal women. Short-term oral estradiol vs placebo. GH feedback tested by pre-infusing GH before GHRP-2 or GHRH stimulation. 10-minute blood sampling with GH deconvolution analysis.

What this study cannot tell us

Small sample inherent to intensive neuroendocrine studies. Oral estradiol (first-pass liver effects) may differ from transdermal. Short-term estrogen may not reflect chronic use.

How to read the evidence

Moderate evidence from a mechanistic RCT with intensive hormonal profiling in the relevant clinical population.

When this study was published

Published in 2001. The estrogen-GH axis interaction continues to inform GH secretagogue prescribing in women.

The bigger picture

Sex hormones profoundly influence the GH axis. This precision — estrogen protecting one GH pathway but not another — reveals the sophisticated interaction between reproductive and somatotropic endocrine systems.

Questions still open

Does transdermal estradiol have the same GHRP-2 protective effect?
Should postmenopausal women on GH secretagogues also receive estrogen?
Does this explain menopause-related GH decline?

Common questions

Does estrogen affect how GH peptides work?

Yes. This study shows estrogen specifically protects the GHRP-2 pathway from GH's self-inhibition. Postmenopausal women (low estrogen) may get less benefit from GHRP-2 unless estrogen is supplemented.

Should women on menopause hormones also take GH peptides?

This study suggests the combination could be beneficial — estrogen enhances GHRP-2's effectiveness by removing a negative feedback brake. However, clinical decisions should be made with a physician.

Read the original research

E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.

The Journal of clinical endocrinology and metabolism, 86(12), 5904-11

View on PubMed ↗

Citation

Anderson, S M; Wideman, L; Patrie, J T; Weltman, A; Bowers, C Y; Veldhuis, J D. (2001). E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.. The Journal of clinical endocrinology and metabolism, 86(12), 5904-11.